About
James M. Daly has served as an ACADIA director since January 2016. He was Executive Vice President and Chief Commercial Officer at Incyte Corporation (2012-2015), earlier held multiple leadership roles at Amgen, and spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline. He currently serves on the boards of argenx SE, Cytokinetics and Madrigal Pharmaceuticals. He earned a B.S. in pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
Roles
Acadia Pharmaceuticals Inc.
Director · Current role
January 2016–present
Incyte Corporation
Executive Vice President and Chief Commercial Officer
October 2012 - June 2015
Amgen, Inc.
Senior Vice President, North America Commercial Operations
2002 - 2012
Glaxo Wellcome / GlaxoSmithKline
Senior Vice President, General Manager (16+ years)
—
External Roles
argenx SE
Director
—
Cytokinetics, Incorporated
Director
—
Madrigal Pharmaceuticals, Inc.
Director
—
Director Compensation
FY 2025Fees earned or paid in cash
$36,846
ComponentAnnual Board and committee cash retainers earned in FY2025
Option awards
$176,392
ComponentAnnual stock option grant, ASC 718 grant-date fair value
Stock awards
$180,705
ComponentAnnual restricted stock unit grant, ASC 718 grant-date fair value
Total
$393,942
Also at Acadia Pharmaceuticals Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.